GSK plc

GSK plc is undergoing an overhaul of its research and development division, leading to job cuts. Despite the cuts, GSK plc is increasing its R&D investment, focusing on new medicines with multi-blockbuster potential. The company expects revenue and operating profit growth.

GSK plc's RSV vaccine, Respiratory syncytial virus vaccine, received expanded age indication approval from the United States United States===Food and Drug Administration, which is expected to support long-term growth objectives and increase market share. This approval allows Respiratory syncytial virus vaccine to be used in a broader adult population, addressing a significant medical need.

GSK plc, through Kim Branson, co-authored the study, emphasizing the need for stricter evaluation protocols for AI in pathology. This involvement highlights GSK plc's commitment to robust AI development in healthcare.

GSK plc is the acquirer of RAPT Therapeutics, and the terms of this acquisition are under investigation by Halper Sadeh LLC.

GSK plc had senior leaders participate in the BIOSeedin Winter Innovation Partnering Summit, contributing to discussions on global strategies and innovation in the biopharmaceutical industry.